Tenpoint Therapeutics secured FDA approval for Yuvezzi, the first dual‑agent ophthalmic drop for presbyopia combining carbachol and brimonidine. The clearance positions Tenpoint against single‑mechanism topical competitors and opens a commercial pathway in an established OTC/clinic market. Concurrently, Tenpoint closed up to $235 million in financing—a mix of equity and a $150 million senior loan—to underwrite commercialization and initial market launch. The combined regulatory and financing milestone reduces go‑to‑market risk for Yuvezzi and signals investor confidence in specialty ophthalmic injectables and drops that can scale rapidly with proper commercial investment.